Etsegenet Ayele, MD
Internal Medicine · Los Alamitos, CANPI 1588752778
Payments from drug & device makers
Across 1,441 payments — averaging $848.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$616K
- Eli Lilly$279K
- Merck$158K
- AstraZeneca$140K
- Pfizer$27K
- Lilly USA, LLC$972
- plus $2K from 30 others
Across 15 payments — averaging $663.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$8K
- Novo Nordisk AS$2K
What the payments were for
- Speaking & faculty fees$4056%
- Travel & lodging$1,95030%
- Food & beverage$4,06163%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 1,207 | $616,375 |
| Eli Lilly | 12 | $278,857 |
| Merck | 20 | $158,081 |
| AstraZeneca | 12 | $139,889 |
| Pfizer | 10 | $26,774 |
| Lilly USA, LLC | 50 | $972 |
| Vanda Pharmaceuticals Inc. | 32 | $429 |
| Boehringer Ingelheim | 8 | $206 |
| GSK | 7 | $173 |
| Novo Nordisk | 12 | $166 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $160 |
| Idorsia Pharmaceuticals US Inc | 2 | $121 |
| Amarin Pharma, Inc. | 5 | $112 |
| Novartis | 5 | $111 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
| Eisai Inc. | 4 | $92 |
| AbbVie(2 entities) | 5 | $83 |
| Amgen(2 entities) | 4 | $78 |
| Xeris Pharmaceuticals, Inc. | 3 | $67 |
| Neurocrine Biosciences, Inc. | 2 | $67 |
| Sunovion Pharmaceuticals Inc. | 3 | $63 |
| Bayer | 2 | $44 |
| Astellas Pharma US Inc | 2 | $44 |
| UCB, Inc. | 1 | $38 |
| Globus Medical | 1 | $34 |
| Lundbeck LLC | 1 | $34 |
| Intra-sana Laboratories | 2 | $32 |
| Abbott | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Nalpropion Pharmaceuticals LLC | 1 | $21 |
| Urovant Sciences Inc | 1 | $20 |
| Biogen | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LAGEVRIO$2,055
How this compares
$1,223,391 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 398 | $145,718 |
| JardianceEmpagliflozin | 140 | $117,040 |
| Invega SustennaPaliperidone Palmitate | 12 | $44,398 |
| RybelsusSemaglutide | 22 | $32,362 |
| XareltoRivaroxaban | 97 | $29,690 |
| OzempicSemaglutide | 19 | $28,575 |
| EntrestoSacubitril/Valsartan | 42 | $22,671 |
| JanuviaSitagliptin Phosphate | 30 | $18,917 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $16,679 |
| JanumetSitagliptin Phos/Metformin Hcl | 38 | $16,308 |
| MyrbetriqMirabegron | 35 | $13,258 |
| LinzessLinaclotide | 17 | $12,858 |
| Aripiprazole | 50 | $10,584 |
| FarxigaDapagliflozin Propanediol | 12 | $10,212 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 105 | $9,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $26,774 | $149,011410 claims |
| Boehringer IngelheimJardiance | $206 | $117,040140 claims |
| Novo NordiskRybelsus, Ozempic | $166 | $60,93741 claims |
| MerckJanuvia, Janumet | $158,081 | $35,22568 claims |
| NovartisEntresto | $111 | $22,67142 claims |
| GSKTrelegy Ellipta | $173 | $16,67924 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $13,25835 claims |
| AbbVieLinzess | $83 | $12,85817 claims |
| AstraZenecaFarxiga | $139,889 | $10,21212 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $5,84212 claims |
| AmgenEpogen | $78 | $5,32123 claims |
| Lilly USA, LLCOlanzapine | $972 | $2,69261 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Alamitos
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.